The post Test appeared first on Ģ����Ƶ.

Goldman, Sachs & Co. and Citigroup Global Markets Inc. are acting as joint book-running managers for the proposed offering. Jefferies LLC is acting as co-manager.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on October 15, 2014.

The offering is being made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus relating to these securities may be obtained, when available, from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, by facsimile at (212)��902-9316, or by email at prospectus-ny@ny.email.gs.com, or from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, by email at or by phone at (800)��831-9146.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Ģ����Ƶ.

Ģ����Ƶ. is a drug development company focusing on innovative therapies for patients with debilitating diseases. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications.

CONTACT: Tina Gullotta, tgullotta@atarabio.com, 415-287-2427

The post Ģ����Ƶ Announces Pricing of Its Initial Public Offering appeared first on Ģ����Ƶ.

Brisbane, CA – [September 23, 2014] – Ģ����Ƶ (Atara) today announced that they have entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies for the treatment of certain cancers and persistent viral infections. Under the terms of the agreement, Atara will have the option to acquire a worldwide license to three clinical stage T-cell therapies consisting of:

• T‑Cells activated against Epstein Barr Virus, or EBV (Phase 2);
• T‑Cells activated against cytomegalovirus, or CMV (Phase 2); and
• T‑Cells activated against Wilms Tumor 1, or WT1 (Phase 1)

These three programs share a common technology under which third-party donor-derived whole blood is collected and enriched for T lymphocytes, or T‑Cells. The T‑Cells are then exposed to certain antigens, and the resulting activated T‑Cells are characterized and stored for future therapeutic use. T‑Cells are a critical component of the body’s immune system and can be harnessed to counteract viral infections and some cancers. By focusing the T‑Cells on specific proteins involved in cancers and infections, the power of the immune system can be employed to combat these diseases.

The EBV program is in Phase 2 and has been dosed in over 100 patients with initial results published in the journal Blood. Richard O’Reilly, MD, Chair of the Department of Pediatrics and Chief of the Pediatric Bone Marrow Transplant Service at MSK, notes that “This collaboration brings the expertise and resources together to expand on the exciting clinical results we’ve observed and will allow us to bring these therapies to a broader patient population.”

MSK will receive cash and Atara common stock in return for the exclusive option. If Atara exercises its option to enter into the license agreement, MSK will receive an upfront license payment and be eligible to receive additional payments based on achievement of certain development, regulatory and sales-related milestones, as well as royalty payments. Atara and MSK have agreed to collaborate on further research to develop additional cellular therapies, which may include T-cell therapies against other antigens and/or chimeric antigen receptor-modified T‑Cells, known as CAR T.

“Our partnership with MSK supports the Atara vision to identify and develop therapies with broad potential to address a number of serious unmet medical needs using innovative science,” said Christopher Haqq, Chief Medical Officer for Atara. “We believe that these off-the-shelf T-cell therapies hold substantial promise for patients who have limited treatment options.”

About Atara

Ģ����Ƶ. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Atara was launched in 2012 by a proven team of drug developers and Kleiner Perkins Caufield & Byers. For more information, please visit www.atarabio.com.

MSK CONTACT: Andrea Baird, bairda@mskcc.org, 212-639-3573

MEDIA CONTACT: Tina Gullotta, tgullotta@atarabio.com, 415-287-2427

INVESTOR CONTACT: Tina Gullotta, tgullotta@atarabio.com, 415-287-2427

The post Ģ����Ƶ Announces Immunotherapy Alliance with Memorial Sloan Kettering Cancer Center appeared first on Ģ����Ƶ.

BRISBANE and THOUSAND OAKS, Calif., April 8, 2014 – Ģ����Ƶ., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has strengthened its board of directors and executive team by appointing Matthew K. Fust as a director and hiring Mitchall G. Clark, B.Pharm, as chief regulatory and quality assurance officer.

Mr. Fust most recently served for five years as executive vice president and chief financial officer of Onyx Pharmaceuticals, where his responsibilities included the corporate finance, accounting, and information technology organizations, along with other operating functions at the company. Prior to Onyx, Fust spent more than five years as senior vice president and chief financial officer of Palo Alto, California-based Jazz Pharmaceuticals, and prior to that he was CFO at Mountain View, California-based Perlegen Sciences and at Mountain View, California-based ALZA Corporation. Fust currently serves as a board member and audit committee chair at Rockville, Maryland-based MacroGenics, South San Francisco, California-based Sunesis Pharmaceuticals, and Novato, California-based Ultragenyx Pharmaceutical.

Prior to joining Atara, Mr. Clark was senior vice president, regulatory affairs at Los Angeles-based Nantworks Group of Companies where he established the regulatory affairs function. Prior to that he was senior vice president, regulatory affairs at Abraxis where he led the regulatory team responsible for the global regulatory approvals of Abraxane® at Celgene Corporation after the Abraxis acquisition. In addition, Clark spent more than 13 years in senior management positions at a number of pharmaceutical companies including American Pharmaceutical Partners, Inc. and VivoRX, Inc.

“We have sought to build a board and management team that have world class biopharmaceutical credentials,” said Isaac Ciechanover, MD, chief executive officer of Atara.�� “We are fortunate that these two seasoned and accomplished individuals have chosen to join the Atara team.�� Matt is a leader in pharmaceutical company management and finance, and his experience and guidance will be a great asset to the board and the entire organization. ��Mitch Clark is also a recognized industry leader and has broad experience in regulatory affairs, having built companies from formation through commercialization. His experience taking compounds from IND to approval on aggressive schedules should serve Atara, and ultimately patients, well.”

About Ģ����Ƶ

Ģ����Ƶ. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications.�� Atara was launched in 2012 by a proven team of drug developers, and Kleiner Perkins Caufield & Byers.�� For more information, please visit www.atarabio.com.

Investor Ģ����Ƶ:
Matt Clawson
matt@allencaron.com
949-474-4300

Media Ģ����Ƶ:
Dan Budwick, Pure Communications
dan@purecommunicationsinc.com
973-271-6085

The post Ģ����Ƶ Strengthens Board; Senior Management Team appeared first on Ģ����Ƶ.

BRISBANE, Calif. and THOUSAND OAKS, Calif., January 10, 2013 – Ģ����Ƶ., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today a second closing of its recently announced Series B financing, bringing the total raised this round to $52 million. Investors in the Series B include , The Baupost Group, (Nasdaq: CELG), , , and .

Proceeds will be used to accelerate the clinical development of Atara’s two lead programs, PINTA 745 and STM 434, which are expected to generate new clinical data within the next 18 months.�� PINTA 745 is a myostatin inhibiting peptibody in Phase 2 development as a potential treatment for protein energy wasting (PEW), a form of inflammation, malnutrition and muscle wasting in patients with end-stage renal disease. STM 434, an inhibitor of activin, represents a novel targeted approach for the treatment of ovarian cancer as well as other solid tumors.�� The Atara team plans to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a first-in-human, Phase 1 study of STM 434.

In addition, Atara announced that Isaac Ciechanover, M.D., chief executive officer, is scheduled to present at the 32^nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014 at 3:30 p.m. PST in San Francisco.

About Ģ����Ƶ

Ģ����Ƶ. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. The research of Atara and its family of companies is based on groundbreaking discoveries regarding the ability of activin, myostatin and other biological targets to change the course of disease progression. Atara has three novel biologics in development, including PINTA 745 (Phase 2) for protein energy wasting in end-stage renal disease, STM 434 (IND-ready) for ovarian cancer and other solid tumors, and NINA 842 (pre-clinical) for cancer-related cachexia. Atara and its family of companies were launched in 2012 by a proven team of drug developers, Amgen, and Kleiner Perkins Caufield & Byers.�� For more information, please visit www.atarabio.com.

Media Ģ����Ƶ:
Dan Budwick, Pure Communications
973-271-6085
dan@purecommunicationsinc.com

Investor Ģ����Ƶ:
Matt Clawson
949-474-4300
matt@allencaron.com

The post Ģ����Ƶ Announces Second Closing of $52 Million Series B Financing appeared first on Ģ����Ƶ.

BRISBANE, Calif. and THOUSAND OAKS, Calif., December 17, 2013 – Ģ����Ƶ., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has secured $38.5 million in initial closings under its Series B financing. In this round, investors (Nasdaq: AMGN), (Nasdaq: CELG), and , joined existing investors Alexandria Venture Investments, , , and ,

Proceeds will be used to accelerate the clinical development of Atara’s two lead programs, PINTA 745 and STM 434, which are expected to generate new clinical data within the next 18 months.

“We founded Atara with the goal of accelerating the development of novel biologic compounds to bring meaningful therapeutic advances to conditions underserved by innovation in recent years,” said Isaac Ciechanover, MD, chief executive officer of Atara.�� “This financing allows us to advance our pipeline and moves us closer to achieving our mission of addressing substantial unmet medical needs.”

Within only 15 months of its founding, the Atara team initiated a Phase 2 pilot trial of PINTA 745, a myostatin inhibiting peptibody, being investigated as a potential treatment for protein energy wasting (PEW), a form of inflammation, malnutrition and muscle wasting in patients with end-stage renal disease. PEW is a condition that correlates with adverse outcomes and increased mortality in patients with chronic renal disease receiving dialysis.�� This condition affects a significant proportion of the 400,000 patients in the US who annually undergo treatment with dialysis. ��The goals of this Phase 2 trial are to assess PINTA 745 potential effects on lean body mass, physical function, quality of life and other outcomes for these patients.

In addition, the Atara team plans to submit an investigational new drug (IND) application to the US Food and Drug Administration to conduct a first-in-human, Phase 1 study of STM 434, an inhibitor of activin.�� STM 434 represents a novel targeted approach for the treatment of ovarian cancer as well as other solid tumors. ����Considered the deadliest cancer for women, ovarian cancer kills approximately 125,000 globally each year.�� Pre-clinical data with Atara’s activin inhibitors suggest an anti-tumor effect as a single agent and additive benefit in combination with chemotherapy.

In conjunction with the financing, Atara announced that it has appointed Joel Marcus, chairman, chief executive officer, and founder of Alexandria Real Estate Equities, Inc. (NYSE: ARE) / Alexandria Venture Investments to the board of directors of the Atara family of companies.

“Atara has moved quickly to build a pipeline of innovative, targeted therapies designed to address the underlying mechanisms of disease, and disease states for which there are few therapeutic options today,” said Mr. Marcus.�� “The company has employed a strategic business structure that provides optionality for value creation.�� I am honored to join the board and the world-class team that Isaac is assembling.”

The financing described above relates to three biotechnology entities – Nina Biotherapeutics, Inc., Pinta Biotherapeutics, Inc., and Santa Maria Biotherapeutics, Inc. – in the Atara family of companies.�� Atara’s unique structure was designed to help enable investors to preserve optionality and maximize potential value creation.�� Atara has raised more than $58 million to date for this family of companies.

About Ģ����Ƶ

Ģ����Ƶ. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. The research of Atara and its family of companies is based on groundbreaking discoveries regarding the ability of activin, myostatin and other biological targets to change the course of disease progression.�� Atara has three novel biologics in development, including PINTA 745 (Phase 2) for protein energy wasting in end-stage renal disease, STM 434 (IND-ready) for ovarian cancer and other solid tumors, and NINA 842 (pre-clinical) for cancer-related cachexia. ����Atara and its family of companies were launched in 2012 by a proven team of drug developers, Amgen, and Kleiner Perkins Caufield & Byers.�� For more information, please visit www.atarabio.com.

Investor Ģ����Ƶ:
Matt Clawson
matt@allencaron.com
949-474-4300

Media Ģ����Ƶ:
Dan Budwick, Pure Communications
dan@purecommunicationsinc.com
973-271-6085

The post Ģ����Ƶ Secures $38.5 Million Series B Financing appeared first on Ģ����Ƶ.

The post Research Findings Presented at 2013 ASCO Annual Meeting appeared first on Ģ����Ƶ.

Amgen to License Pipeline Assets to Newly Formed Company

THOUSAND��OAKS, Calif. and��MENLO��PARK, Calif. (Oct. 25, 2012) – Amgen and Kleiner Perkins Caufield & Byers (KPCB) today announced the formation of Ģ����Ƶ, (www.atarabio.com), a new drug development company with a focus on innovative therapies for patients with chronic diseases in therapeutic areas including nephrology and oncology. Ģ����Ƶ will have licenses to six Amgen assets, which are in various stages of development, ranging from preclinical to Phase 1. Financial terms of the transaction are not being disclosed.

Ģ����Ƶ will be financed initially by��KPCB, and Isaac Ciechanover, M.D., a former partner at KPCB, will serve as the president and chief executive officer. Amgen will have a minority equity interest in Ģ����Ƶ.

“Amgen is excited to partner with��KPCB��to help advance molecules in Amgen’s pipeline that have the potential to treat serious illnesses,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “With facilities in both the Bay Area and near Amgen’s Thousand Oaks campus, Ģ����Ƶ will provide the opportunity to further foster biotechnology innovation in Amgen’s communities.”

“We look forward to building on Amgen’s research to bring a promising group of therapeutics to patients with serious illnesses,” said Ciechanover.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about our pioneering science and our vital medicines, visit . Follow us on .

About Kleiner Perkins
Kleiner Perkins Caufield & Byers (KPCB) has backed entrepreneurs in more than 500 ventures leading to 150 IPOs, 350,000 jobs and a deep strategic network. The firm has helped build pioneering companies like Align, Amazon, Electronic Arts, Genentech, Genomic Health, Google, Intuit, Juniper Networks, Netscape, Symantec, VeriSign and WebMD.��KPCB��partners serve on the boards of Amazon, Apple, Bloom Energy, Flipboard, Foundation Medicine, Google, Hewlett-Packard, Nest, Square, Tesaro and Zynga, among others.��KPCB��accelerates the success of entrepreneurs with a team of partners delivering company-building services including strategy, operational scaling, recruiting, business development and product delivery. The firm invests in all stages from seed and incubation to growth companies.��KPCB operates from offices in Menlo Park, San Francisco, Shanghai and Beijing. .

Forward-Looking Statements
This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in Amgen’s Form 10-K for the year ended Dec. 31, 2011, and in its periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Amgen’s results may be affected by Amgen’s ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign), difficulties or delays in manufacturing its products. In addition, sales of Amgen products are affected by reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others’ regulations and reimbursement policies may affect the development, usage and pricing of Amgen products. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen or others could identify safety, side effects or manufacturing problems with Amgen products after they are on the market. Amgen’s business may be impacted by government investigations, litigation and products liability claims. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors. Amgen depends on third parties for a significant portion of its manufacturing capacity for the supply of certain of its current and future products and limits on supply may constrain sales of certain of its current products and product candidate development. In addition, Amgen competes with other companies with respect to some of its marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for Amgen products are supplied by sole third-party suppliers. Amgen’s business performance could affect or limit the ability of its Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock.

The post Amgen and KPCB Partner to Create Ģ����Ƶ appeared first on Ģ����Ƶ.